CDKI-73 is a novel and potent CDK9 inhibitor with Ki of 4 nM.

RGB-286638 2HCl, the dihydrochloride salt of RGB-286638, is a multi-targeted cyclin-dependent kinase (CDK) inhibitor.

ML167 (also called CID-44968231; NCGC-00188654; ML-167; CID 44968231; NCGC00188654) is a novel, ATP-competitive and highly selective Cdc2-like kinase 4 (Clk4) inhibitor with potential anticancer activity.

Simurosertib (formerly known as TAK-931) is a novel, selective and orally bioavailable cycle 7 (CDC7, cell division cycle 7-related protein) kinase inhibitor with anticancer activity.

(E/Z)-Zotiraciclib HCl (TG02 HCl) is a novel and potent CDK2, JAK2, and FLT3 inhibitor with the potential for the treatment of cancer.

Purvalanol B (formerly known as NG-95) is a potent and selective cyclin-dependent kinase (CDK) inhibitor, inhibiting Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p35, and Cdk2/cyclin B (IC50s = 6, 9, 6, and 6 nM, respectively.

Riviciclib HCl (P276-00) is a flavonoid analog which acts as a novel inhibitor of CDK1 (cyclin-dependent kinase), CDK4 and CDK9 with IC50 of 79 nM, 63 nM and 20 nM, respectively.

BMS-265246 (BMS265246; BMS 265246) is a novel, potent and selective CDK1/2 (Cyclin-dependent kinases) inhibitor with potential antitumor activity.

LDC4297 is a novel and potent CDK7 (Cyclin-dependent protein kinase 7) inhibitor with IC50 of 0.13±0.06 nM for CDK7 and IC50s between 10 nM and 10,000 nM for all other analyzed CDKs.

SNS-032 (also known as BMS-387032; SNS 032; BMS387032; SNS032), a 2-aminothiazole based small-molecule, is a potent and selective inhibitor of CDK2 (cyclin dependent kinase 2) with potential antitumor activity.